Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF FINANCIAL OFFICER | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 20,854 |
Ending reported balance
After 2026-09-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 2,694 · Balance 18,848 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 2 · 2026-09-01 · Exercise / conversion · Acquired 1,750 · Balance 20,598 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 3 · 2026-09-01 · Exercise / conversion · Acquired 1,591 · Balance 22,189 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 4 · 2026-09-01 · Exercise / conversion · Acquired 3,069 · Balance 25,258 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 5 · 2026-09-01 · Tax withholding · Disposed 4,404 · Balance 20,854 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 7,800 |
Reported balance
After 2026-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-01 · Grant · Acquired 7,800 · Balance 7,800 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 9,206 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Exercise / conversion · Disposed 3,069 · Balance 9,206 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 3,182 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Exercise / conversion · Disposed 1,591 · Balance 3,182 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 1,750 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 1,750 · Balance 1,750 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 2,694 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 31,150 |
Reported balance
After 2026-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-01 · Grant · Acquired 31,150 · Balance 31,150 F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.
F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001835458-26-000012 · form4-09032026_080953.xml · derivative · entry 11 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 2,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001835458-26-000012 · form4-09032026_080953.xml · derivative · entry 10 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,750 Underlying: Class A Ordinary Share · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001835458-26-000012 · form4-09032026_080953.xml · derivative · entry 9 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,182 Underlying: Class A Ordinary Share · 1,591 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 3,069 | $0.00 | $0.00 |
DisclosureSEC source: 0001835458-26-000012 · form4-09032026_080953.xml · derivative · entry 8 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,206 Underlying: Class A Ordinary Share · 3,069 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 31,150 | $0.00 Strike: $79.28 | $0.00 |
DisclosureSEC source: 0001835458-26-000012 · form4-09032026_080953.xml · derivative · entry 7 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,150 Underlying: Class A Ordinary Share · 31,150 shares Expires 2036-08-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 7,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001835458-26-000012 · form4-09032026_080953.xml · derivative · entry 6 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,800 Underlying: Class A Ordinary Share · 7,800 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 4,404 | $79.28 | $349,149.12 |
DisclosureSEC source: 0001835458-26-000012 · form4-09032026_080953.xml · nonDerivative · entry 5 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,854 Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 3,069 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001835458-26-000012 · form4-09032026_080953.xml · nonDerivative · entry 4 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,591 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001835458-26-000012 · form4-09032026_080953.xml · nonDerivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001835458-26-000012 · form4-09032026_080953.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:49 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001835458-26-000012 · form4-09032026_080953.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001835458-26-000010 · form4-04082026_080407.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 2,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 1,303 | $48.94 | $63,768.82 |
DisclosureSEC source: 0001835458-26-000010 · form4-04082026_080407.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,154 Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001835458-26-000010 · form4-04082026_080407.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001835458-26-000008 · form4-04032026_080402.xml · derivative · entry 8 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,536 Underlying: Class A Ordinary Share · 1,846 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F8 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025. F8 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001835458-26-000008 · form4-04032026_080402.xml · derivative · entry 7 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,182 Underlying: Class A Ordinary Share · 1,591 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001835458-26-000008 · form4-04032026_080402.xml · derivative · entry 6 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,750 Underlying: Class A Ordinary Share · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 15,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001835458-26-000008 · form4-04032026_080402.xml · derivative · entry 5 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,600 Underlying: Class A Ordinary Share · 15,600 shares Expires not disclosed F4 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee F5 · derivative.exercise_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2029, unless such date falls on a non-business date, in which case the next business date shall apply. F5 · derivative.expiration_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2029, unless such date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 7,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001835458-26-000008 · form4-04032026_080402.xml · derivative · entry 4 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,800 Underlying: Class A Ordinary Share · 7,800 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter. F3 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 31,150 | $0.00 Strike: $48.13 | $0.00 |
DisclosureSEC source: 0001835458-26-000008 · form4-04032026_080402.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,150 Underlying: Class A Ordinary Share · 31,150 shares Expires 2036-03-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April1, 2026. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 2,510 | $48.13 | $120,806.30 |
DisclosureSEC source: 0001835458-26-000008 · form4-04032026_080402.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,763 Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 5,187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001835458-26-000008 · form4-04032026_080402.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 10,360 | $0.00 Strike: $26.74 | $0.00 |
DisclosureSEC source: 0001835458-26-000006 · form4-03112026_080357.xml · derivative · entry 10 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,790 Underlying: Class A Ordinary Share · 10,360 shares Expires 2034-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. F7 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2024. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 13,813 | $0.00 Strike: $18.06 | $0.00 |
DisclosureSEC source: 0001835458-26-000006 · form4-03112026_080357.xml · derivative · entry 9 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,337 Underlying: Class A Ordinary Share · 13,813 shares Expires 2034-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. F6 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2024. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 10,513 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0001835458-26-000006 · form4-03112026_080357.xml · derivative · entry 8 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,396 Underlying: Class A Ordinary Share · 10,513 shares Expires 2033-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 2,036 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001835458-26-000006 · form4-03112026_080357.xml · derivative · entry 7 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 2,036 shares Expires 2031-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 18,741 | $46.24 | $866,583.84 |
DisclosureSEC source: 0001835458-26-000006 · form4-03112026_080357.xml · nonDerivative · entry 6 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,086 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.89 and $46.79. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff fullinformation regarding the number of Shares sold at each price. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 17,981 | $45.58 | $819,573.98 |
DisclosureSEC source: 0001835458-26-000006 · form4-03112026_080357.xml · nonDerivative · entry 5 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,827 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $44.885 and $45.88. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 10,360 | $26.74 | $277,026.40 |
DisclosureSEC source: 0001835458-26-000006 · form4-03112026_080357.xml · nonDerivative · entry 4 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 13,813 | $18.06 | $249,462.78 |
DisclosureSEC source: 0001835458-26-000006 · form4-03112026_080357.xml · nonDerivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 10,513 | $17.76 | $186,710.88 |
DisclosureSEC source: 0001835458-26-000006 · form4-03112026_080357.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,036 | $22.89 | $46,604.04 |
DisclosureSEC source: 0001835458-26-000006 · form4-03112026_080357.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 2,471 | $0.00 Strike: $16.90 | $0.00 |
DisclosureSEC source: 0001835458-26-000004 · form4-02112026_090228.xml · derivative · entry 6 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 2,471 shares Expires 2031-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 8,374 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0001835458-26-000004 · form4-02112026_090228.xml · derivative · entry 5 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 8,374 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 8,731 | $43.72 | $381,719.32 |
DisclosureSEC source: 0001835458-26-000004 · form4-02112026_090228.xml · nonDerivative · entry 4 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,086 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $43.35 and $44.18. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff fullinformation regarding the number of Shares sold at each price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 9,114 | $42.85 | $390,534.90 |
DisclosureSEC source: 0001835458-26-000004 · form4-02112026_090228.xml · nonDerivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,817 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $42.35 and $43.345. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff fullinformation regarding the number of Shares sold at each price. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,471 | $16.90 | $41,759.90 |
DisclosureSEC source: 0001835458-26-000004 · form4-02112026_090228.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 8,374 | $12.97 | $108,610.78 |
DisclosureSEC source: 0001835458-26-000004 · form4-02112026_090228.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 12,000 | $41.89 | $502,680.00 |
DisclosureSEC source: 0001835458-26-000002 · form4-01092026_090138.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,086 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.44 and $42.24. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 10,512 | $0.00 Strike: $10.76 | $0.00 |
DisclosureSEC source: 0001835458-25-000007 · form4-12102025_101258.xml · derivative · entry 7 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,016 Underlying: Class A Ordinary Share · 10,512 shares Expires 2033-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 16,165 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001835458-25-000007 · form4-12102025_101258.xml · derivative · entry 6 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,123 Underlying: Class A Ordinary Share · 16,165 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. F4 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 16,164 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001835458-25-000007 · form4-12102025_101258.xml · derivative · entry 5 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,388 Underlying: Class A Ordinary Share · 16,164 shares Expires 2032-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 42,841 | $41.49 | $1,777,473.09 |
DisclosureSEC source: 0001835458-25-000007 · form4-12102025_101258.xml · nonDerivative · entry 4 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,086 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.20 and $42.08. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 10,512 | $10.76 | $113,109.12 |
DisclosureSEC source: 0001835458-25-000007 · form4-12102025_101258.xml · nonDerivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 16,165 | $11.97 | $193,495.05 |
DisclosureSEC source: 0001835458-25-000007 · form4-12102025_101258.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 22:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 16,164 | $11.10 | $179,420.40 |
DisclosureSEC source: 0001835458-25-000007 · form4-12102025_101258.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 19,900 | $0.00 Strike: $30.93 | $0.00 |
DisclosureSEC source: 0001835458-25-000005 · form4-11142025_091151.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 19,900 shares Expires 2028-09-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 19,900 | $40.94 | $814,706.00 |
DisclosureSEC source: 0001835458-25-000005 · form4-11142025_091151.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,086 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $40.93 and $41.035. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 19,900 | $30.93 | $615,507.00 |
DisclosureSEC source: 0001835458-25-000005 · form4-11142025_091151.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| October 28, 2025 Filed Oct 30, 2025 20:47 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 100 | $0.00 Strike: $30.93 | $0.00 |
DisclosureSEC source: 0001835458-25-000003 · form4-10302025_081002.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,900 Underlying: Class A Ordinary Share · 100 shares Expires 2028-09-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.